Prevalence of systemic immunoreactivity to Aggregatibacter actinomycetemcomitansleukotoxin in relation to the incidence of myocardial infarction
Abstract Background Chronic infections and associated inflammatory markers are suggested risk factors for cardiovascular disease (CVD). The proinflammatory cytokine, interleukin (IL)-1β, is suggested to play a role in the regulation of local inflammatory responses in both CVD and periodontitis. The...
Main Authors: | , , , , , , |
---|---|
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
BioMed Central Ltd.
2011
|
Subjects: | |
Online Access: | http://www.biomedcentral.com/1471-2334/11/55 |
id |
ftbiomed:oai:biomedcentral.com:1471-2334-11-55 |
---|---|
record_format |
openpolar |
spelling |
ftbiomed:oai:biomedcentral.com:1471-2334-11-55 2023-05-15T17:44:28+02:00 Prevalence of systemic immunoreactivity to Aggregatibacter actinomycetemcomitansleukotoxin in relation to the incidence of myocardial infarction Johansson, Anders Eriksson, Marie Åhrén, Ann-Marie Boman, Kurt Jansson, Jan-Håkan Hallmans, Göran Johansson, Ingegerd 2011-03-01 http://www.biomedcentral.com/1471-2334/11/55 en eng BioMed Central Ltd. http://www.biomedcentral.com/1471-2334/11/55 Copyright 2011 Johansson et al; licensee BioMed Central Ltd. Research article 2011 ftbiomed 2011-03-13T00:35:47Z Abstract Background Chronic infections and associated inflammatory markers are suggested risk factors for cardiovascular disease (CVD). The proinflammatory cytokine, interleukin (IL)-1β, is suggested to play a role in the regulation of local inflammatory responses in both CVD and periodontitis. The leukotoxin from the periodontal pathogen Aggregatibacter actinomycetemcomitans has recently been shown to cause abundant secretion of IL-1β from macrophages. The aim of the present study was to compare the prevalence of systemic immunoreactivity to A. actinomycetemcomitans leukotoxin in myocardial infarction (MI) cases (n = 532) and matched controls (n = 1,000) in a population-based case and referents study in northern Sweden. Methods Capacity to neutralize A. actinomycetemcomitans leukotoxin was analyzed in a bioassay with leukocytes, purified leukotoxin, and plasma. Plasma samples that inhibited lactate-dehydrogenase release from leukotoxin-lysed cells by ≥50% were classified as positive. Results Neutralizing capacity against A. actinomycetemcomitans leukotoxin was detected in 53.3% of the plasma samples. The ability to neutralize leukotoxin was correlated to increasing age in men (n = 1,082) but not in women (n = 450). There was no correlation between presence of systemic leukotoxin-neutralization capacity and the incidence of MI, except for women (n = 146). Women with a low neutralizing capacity had a significantly higher incidence of MI than those who had a high neutralizing capacity. Conclusion Systemic immunoreactivity against A. actinomycetemcomitans leukotoxin was found at a high prevalence in the analyzed population of adults from northern Sweden. The results from the present study do not support the hypothesis that systemic leukotoxin-neutralizing capacity can decrease the risk for MI. Article in Journal/Newspaper Northern Sweden BioMed Central |
institution |
Open Polar |
collection |
BioMed Central |
op_collection_id |
ftbiomed |
language |
English |
description |
Abstract Background Chronic infections and associated inflammatory markers are suggested risk factors for cardiovascular disease (CVD). The proinflammatory cytokine, interleukin (IL)-1β, is suggested to play a role in the regulation of local inflammatory responses in both CVD and periodontitis. The leukotoxin from the periodontal pathogen Aggregatibacter actinomycetemcomitans has recently been shown to cause abundant secretion of IL-1β from macrophages. The aim of the present study was to compare the prevalence of systemic immunoreactivity to A. actinomycetemcomitans leukotoxin in myocardial infarction (MI) cases (n = 532) and matched controls (n = 1,000) in a population-based case and referents study in northern Sweden. Methods Capacity to neutralize A. actinomycetemcomitans leukotoxin was analyzed in a bioassay with leukocytes, purified leukotoxin, and plasma. Plasma samples that inhibited lactate-dehydrogenase release from leukotoxin-lysed cells by ≥50% were classified as positive. Results Neutralizing capacity against A. actinomycetemcomitans leukotoxin was detected in 53.3% of the plasma samples. The ability to neutralize leukotoxin was correlated to increasing age in men (n = 1,082) but not in women (n = 450). There was no correlation between presence of systemic leukotoxin-neutralization capacity and the incidence of MI, except for women (n = 146). Women with a low neutralizing capacity had a significantly higher incidence of MI than those who had a high neutralizing capacity. Conclusion Systemic immunoreactivity against A. actinomycetemcomitans leukotoxin was found at a high prevalence in the analyzed population of adults from northern Sweden. The results from the present study do not support the hypothesis that systemic leukotoxin-neutralizing capacity can decrease the risk for MI. |
format |
Article in Journal/Newspaper |
author |
Johansson, Anders Eriksson, Marie Åhrén, Ann-Marie Boman, Kurt Jansson, Jan-Håkan Hallmans, Göran Johansson, Ingegerd |
spellingShingle |
Johansson, Anders Eriksson, Marie Åhrén, Ann-Marie Boman, Kurt Jansson, Jan-Håkan Hallmans, Göran Johansson, Ingegerd Prevalence of systemic immunoreactivity to Aggregatibacter actinomycetemcomitansleukotoxin in relation to the incidence of myocardial infarction |
author_facet |
Johansson, Anders Eriksson, Marie Åhrén, Ann-Marie Boman, Kurt Jansson, Jan-Håkan Hallmans, Göran Johansson, Ingegerd |
author_sort |
Johansson, Anders |
title |
Prevalence of systemic immunoreactivity to Aggregatibacter actinomycetemcomitansleukotoxin in relation to the incidence of myocardial infarction |
title_short |
Prevalence of systemic immunoreactivity to Aggregatibacter actinomycetemcomitansleukotoxin in relation to the incidence of myocardial infarction |
title_full |
Prevalence of systemic immunoreactivity to Aggregatibacter actinomycetemcomitansleukotoxin in relation to the incidence of myocardial infarction |
title_fullStr |
Prevalence of systemic immunoreactivity to Aggregatibacter actinomycetemcomitansleukotoxin in relation to the incidence of myocardial infarction |
title_full_unstemmed |
Prevalence of systemic immunoreactivity to Aggregatibacter actinomycetemcomitansleukotoxin in relation to the incidence of myocardial infarction |
title_sort |
prevalence of systemic immunoreactivity to aggregatibacter actinomycetemcomitansleukotoxin in relation to the incidence of myocardial infarction |
publisher |
BioMed Central Ltd. |
publishDate |
2011 |
url |
http://www.biomedcentral.com/1471-2334/11/55 |
genre |
Northern Sweden |
genre_facet |
Northern Sweden |
op_relation |
http://www.biomedcentral.com/1471-2334/11/55 |
op_rights |
Copyright 2011 Johansson et al; licensee BioMed Central Ltd. |
_version_ |
1766146688160890880 |